← Back to Search

Procedure

AI-Guided Ablation for Ventricular Tachycardia in Heart Disease (AIM-VT Trial)

N/A

Waitlist Available

Led By Henry Huang, MD

Research Sponsored by Rush University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient must be 18 years or older

Patient must have Ischemic Cardiomyopathy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

AIM-VT Trial Summary

This trial will study if using a new measure (AI) of lesion quality during ablation for ventricular arrhythmias (VA) improves outcomes for patients with heart disease.

Who is the study for?

This trial is for adults over 18 with Ischemic Cardiomyopathy who've had a specific type of irregular heartbeat (Scar-related Monomorphic Ventricular Tachycardia) confirmed by ECG or device check. It's not for those with other heart rhythm problems, recent heart attacks or surgery, severe valve issues, recent stroke/TIA, the worst class of heart failure symptoms, or non-ischemic causes.Check my eligibility

What is being tested?

The study compares two ways to treat irregular heartbeats using radiofrequency catheter ablation: one group gets standard treatment without Ablation Index guidance and the other uses AI-guidance aiming for more precise lesion creation. The goal is to see if AI-guidance shortens procedure time.See study design

What are the potential side effects?

Potential side effects from ventricular tachycardia ablation can include discomfort at the site where catheters are inserted, bleeding or bruising there, damage to blood vessels or heart tissue during the procedure and risks associated with sedation.

AIM-VT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with Ischemic Cardiomyopathy.

AIM-VT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage reduction in ablation time between the groups with/without AI guidance

Secondary outcome measures

Fluoroscopy duration in minutes

Percentage of reduction in total procedural duration in seconds between the AI/not AI group

Total intravenous fluids administered in milliliters (ml)

Other outcome measures

Ablation Index per lesion (absolute value and percentage difference)

Acute procedural success (no inducible VT), partial success (only non-clinical VT induced), and inducibility not tested at end of procedure (in number, % and risk-difference)

Average ablation time per lesion (in seconds and percentage difference)

+10 more

AIM-VT Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: AI-guided ablationExperimental Treatment1 Intervention

Use of AI guidance to conduct the ablation

Group II: non-AI guided ablationActive Control1 Intervention

Ablation without AI guidance, AI values masked to the operator.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor

423 Previous Clinical Trials

164,023 Total Patients Enrolled

The Cleveland ClinicOTHER

1,030 Previous Clinical Trials

1,365,458 Total Patients Enrolled

Medical University of South CarolinaOTHER

934 Previous Clinical Trials

7,394,596 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research initiative currently enrolling participants?

"The clinicaltrials.gov entry for this trial confirms that it is not recruiting subjects at the moment. It was initially posted on July 1st 2024 and last updated November 17th 2023, but with 723 other trials actively seeking patients there are still plenty of opportunities to participate in medical research."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

Henry Huang 2024. "Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06138873.

All > Anterior Ischemic Optic Neuropathy